Author

N. Nao

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 12

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 11 Approach:experimental assay· 10 Organism:human· 10 Approach:statistical model· 2 Organism:virus· 2 Organism:chicken / avian· 1 Approach:comparative / phylogenetic analysis· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. Ito· 9 shared R. Suzuki· 9 shared The Genotype to Phenotype Japan (G2P-Japan) Consortium· 9 shared H. Nasser· 8 shared K. Matsuno· 8 shared K. Uriu· 8 shared K. Yoshimatsu· 8 shared L. Wang· 8 shared

Activity by Year

2020-2023 · peak 7/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersMicrobiology

J. Ito

Mutual co-authors in cluster

Author profile →

12 papers

Recent·Most cited

Virological characteristics of the SARS-CoV-2 BA.2.86 variant

T. Tamura, K. Mizuma, H. Nasser, S. Deguchi, M. Padilla-Blanco, K. Uriu, J. E. M. Tolentino, S. Tsujino, R. Suzuki, I. Kojima, N. Nao, R. Shimizu, M. Jonathan, Y. Kosugi, Z. Guo, , K. Sato

This study investigates the virological characteristics of the SARS-CoV-2 BA.2.86 variant, finding it has higher reproduction number than EG.5.1 but lower pathogenicity and replication capacity compared to BA.2.

bioRxiv · Nov 2, 2023Microbiology

Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant

S. Tsujino, S. Deguchi, T. Nomai, M. Padilla-Blanco, A. Plianchaisuk, L. Wang, M. M. Begum, K. Uriu, K. Mizuma, N. Nao, I. Kojima, T. Tsubo, J. Li, Y. Matsumura, M. Nagao, , Za

The paper investigates the virological features of the SARS-CoV-2 EG.5.1 variant, finding its fitness and antiviral sensitivity comparable to XBB.1.5, with structural differences in spike proteins.

bioRxiv · Oct 19, 2023Microbiology

Virological characteristics of the SARS-CoV-2 XBB.1.5 variant

T. Tamura, T. Irie, S. Deguchi, H. Yajima, M. Tsuda, H. Nasser, K. Mizuma, A. Plianchaisuk, S. Suzuki, K. Uriu, M. M. Begum, R. Shimizu, M. Jonathan, R. Suzuki, T. Kondo, , T. Fukuhara

The paper analyzes the virological characteristics of the SARS-CoV-2 XBB.1.5 variant, showing reduced pathogenicity and impaired MHC expression due to mutations in ORF8 and S.

bioRxiv · Aug 16, 2023 · PreprintMicrobiology

Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants

T. Tamura, J. Ito, K. Uriu, J. Zahradnik, I. Kida, H. Nasser, M. Shofa, Y. Oda, S. Lytras, N. Nao, Y. Itakura, S. Deguchi, R. Suzuki, L. Wang, M. M. Begum, , K. Sato

This study identifies XBB as a SARS-CoV-2 variant resulting from recombination of BA.2 subvariants, showing increased resistance to neutralizing antibodies and enhanced fusogenicity compared to BA.2.75.

bioRxiv · Dec 27, 2022 · PreprintMicrobiology

Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant

J. Ito, R. Suzuki, K. Uriu, Y. Itakura, J. Zahradnik, S. Deguchi, L. Wang, S. Lytras, T. Tamura, I. Kida, H. Nasser, M. Shofa, M. M. Begum, M. Tsuda, Y. Oda, , K. Sato

The paper investigates convergent evolution in SARS-CoV-2 Omicron subvariants, identifying five critical spike protein substitutions in BQ.1.1 that enhance viral fitness and antibody resistance.

bioRxiv · Dec 5, 2022Microbiology

Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5

T. Tamura, D. Yamasoba, Y. Oda, J. Ito, T. Kamasaki, N. Nao, R. Hashimoto, Y. Fujioka, R. Suzuki, L. Wang, H. Ito, I. Kimura, I. Yokota, M. Kishimoto, M. Tsuda, , T. Fukuhara

This study compares the pathogenicity of SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.5, finding BA.5 is more fusogenic and induces stronger inflammation than earlier variants.

bioRxiv · Aug 5, 2022Microbiology

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75

A. Saito, T. Tamura, J. Zahradnik, S. Deguchi, K. Tabata, I. Kimura, J. Ito, H. Nasser, M. Toyoda, K. Nagata, K. Uriu, Y. Kosugi, S. Fujita, D. Yamasoba, M. Shofa, , Kei Sato

This study investigates the virological characteristics of SARS-CoV-2 Omicron BA.2.75, finding it has higher transmissibility and pathogenicity compared to BA.2 and BA.5, but similar sensitivity to antiviral drugs.

bioRxiv · Jul 14, 2022Microbiology

Diagnosis and early prediction of lymphoma using high-throughput clonality analysis of bovine leukemia virus-infected cells

T. Okagawa, H. Shimakura, S. Konnai, M. Saito, T. Matsudaira, N. Nao, S. Yamada, K. Murakami, N. Maekawa, S. Murata, K. Ohashi

This study evaluates RAISING-CLOVA's ability to detect clonality in BLV-infected cells, showing high sensitivity and specificity in distinguishing EBL from non-EBL cattle and confirming its utility for early detection.

bioRxiv · Jun 6, 2022Microbiology

Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5

I. Kimura, D. Yamasoba, T. Tamura, N. Nao, Y. Oda, S. Mitoma, J. Ito, H. Nasser, J. Zahradnik, K. Uriu, S. Fujita, Y. Kosugi, L. Wang, M. Tsuda, M. Kishimoto, , K. Sato

This study analyzes the virological characteristics of SARS-CoV-2 Omicron variants BA.2.12.1, BA.4, and BA.5, finding they have higher reproduction numbers, reduced neutralization by prior immunity, increased replication in lung cells, and greater pathogenicity in hamsters compared to BA.2.

bioRxiv · May 26, 2022Microbiology

Virological characteristics of SARS-CoV-2 BA.2 variant

D. Yamasoba, I. Kimura, H. Nasser, Y. Morioka, N. Nao, J. Ito, K. Uriu, M. Tsuda, J. Zahradnik, K. Shirakawa, R. Suzuki, M. Kishimoto, Y. Kosugi, K. Kobiyama, T. Hara, , Sawa

This study compares the virological characteristics of SARS-CoV-2 BA.2 and BA.1 variants, finding BA.2 has higher transmissibility, different antigenicity, greater replicative capacity, and higher pathogenicity in hamsters.

bioRxiv · Feb 14, 2022Microbiology

The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells

S. Matsuyama, M. Kawase, N. Nao, K. Shirato, M. Ujike, W. Kamitani, M. Shimojima, S. Fukushi

This paper identifies ciclesonide as an inhaled corticosteroid that inhibits SARS-CoV-2 replication by targeting the viral replication-transcription complex in cultured cells.

bioRxiv · Aug 22, 2020Microbiology

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

S. Matsuyama, M. Kawase, N. Nao, K. Shirato, M. Ujike, W. Kamitani, M. Shimojima, S. Fukushi

The paper identifies ciclesonide as a corticosteroid that inhibits coronavirus replication by targeting NSP15, with resistance emerging through an amino acid substitution.

bioRxiv · Mar 11, 2020 · PreprintMicrobiology